COVID-19 Therapeutics Strategy: Commission identifies five promising
candidate therapeutics *
Brussels, 29 June 2021
“Vaccination against COVID-19 offers the best way to end the pandemic and get back to a
normal life. In parallel, we are working to have the best treatments available for those who
are infected.” *
The EU Strategy on COVID-19 Therapeutics delivers today its first outcome, with the announcement
of the first portfolio of five therapeutics that could soon be available to treat patients across the EU.
Four of these therapeutics are monoclonal antibodies under rolling review by the European Medicines
Agency. Another one is an immunosuppressant, which has a marketing authorisation that could be
extended to include the treatment of COVID-19 patients.
Commissioner for Health and Food Safety, Stella Kyriakides, said: “Today we are taking the first
step towards a broad portfolio of therapeutics to treat COVID-19. Whilst vaccination is progressing at
increasing speed, the virus will not disappear and patients will need safe and effective treatments to
reduce the burden of COVID-19. Our goal is clear, we aim to identify more front-runner candidates
under development and authorise at least three new therapeutics by the end of the year. This is the
European Health Union in action.”
The five products are in an advanced stage of development and have a high potential to be among
the three new COVID-19 therapeutics to receive authorisation by October 2021, the target set under
the Strategy, provided the final data demonstrate their safety, quality and efficacy.
- Forums
- Breaking News
- COVID AND THE VACCINE - TRUTH, LIES, AND MISCONCEPTIONS REVEALED
COVID-19 Therapeutics Strategy: Commission identifies five...
- There are more pages in this discussion • 84,196 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)